FindTrial
Sign In

A multicentre phase III randomised controlled study of Theratope vaccine for metastatic breast cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN91516565
Enrollment
Unknown
Registered
2002-08-19
Start date
2000-01-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Breast

Interventions

1. Theratope s/c injections 100 mg with detox at weeks 0, 2, 5 and 9 2. Control injection Keyhole limpet heamocyanin 100 mg with detox at weeks 0, 2, 5 and 9

Sponsors

UK Co-ordinating Committee for Cancer Research (UKCCCR)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Must have received 4-8 cycles or 12-24 weeks duration of first line chemotherapy for metastatic disease 2. Has either no evidence of disease of non-progressive disease following first line chemotherapy or stable disease

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026